If approved, Mavenclad could offer a more patient-friendly dosing regimen than existing MS oral drugs. Biogen’s Tecfidera (dimethyl fumarate) is taken twice daily and is associated with ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

which require regular trips to hospital for dosing and monitoring. In contrast, Mavenclad needs to be dosed just 20 times in the first two years of a four-year treatment cycle. The tablets are ...